Brokers Issue Forecasts for Tenax Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:TENX)

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities research analysts at William Blair issued their Q3 2024 EPS estimates for shares of Tenax Therapeutics in a report issued on Monday, September 30th. William Blair analyst M. Phipps forecasts that the specialty pharmaceutical company will post earnings of ($1.50) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($6.68) per share. William Blair also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($1.35) EPS, FY2024 earnings at ($6.90) EPS, FY2025 earnings at ($8.33) EPS, FY2026 earnings at ($9.05) EPS and FY2027 earnings at ($9.63) EPS.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share for the quarter, topping the consensus estimate of ($1.99) by $0.16.

Separately, StockNews.com initiated coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They set a “sell” rating for the company.

Tenax Therapeutics Trading Down 1.7 %

Shares of NASDAQ TENX opened at $3.40 on Wednesday. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $61.20. The company’s 50-day moving average is $3.73 and its 200 day moving average is $3.60.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.